STERIS plc (NYSE:STE) Shares Acquired by Barclays PLC

Barclays PLC increased its stake in shares of STERIS plc (NYSE:STE - Free Report) by 24.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 161,970 shares of the medical equipment provider's stock after purchasing an additional 31,497 shares during the quarter. Barclays PLC owned approximately 0.16% of STERIS worth $33,295,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Magnolia Capital Advisors LLC increased its holdings in shares of STERIS by 1.9% in the fourth quarter. Magnolia Capital Advisors LLC now owns 2,534 shares of the medical equipment provider's stock valued at $521,000 after purchasing an additional 48 shares in the last quarter. SkyView Investment Advisors LLC grew its position in STERIS by 1.6% during the 3rd quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider's stock worth $765,000 after acquiring an additional 51 shares during the last quarter. Park Edge Advisors LLC lifted its position in shares of STERIS by 1.1% during the 4th quarter. Park Edge Advisors LLC now owns 4,662 shares of the medical equipment provider's stock valued at $958,000 after acquiring an additional 51 shares during the period. Citizens Financial Group Inc. RI raised its holdings in shares of STERIS by 5.9% in the fourth quarter. Citizens Financial Group Inc. RI now owns 975 shares of the medical equipment provider's stock valued at $201,000 after purchasing an additional 54 shares during the last quarter. Finally, Opal Wealth Advisors LLC grew its holdings in STERIS by 5.7% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,118 shares of the medical equipment provider's stock valued at $230,000 after purchasing an additional 60 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Stock Performance

Shares of NYSE STE traded up $3.06 during midday trading on Thursday, hitting $226.93. 65,492 shares of the company's stock were exchanged, compared to its average volume of 536,988. The company's 50 day moving average price is $222.65 and its 200 day moving average price is $218.97. The firm has a market capitalization of $22.30 billion, a PE ratio of 48.19 and a beta of 0.87. STERIS plc has a 12 month low of $200.41 and a 12 month high of $248.24. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32.

STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. As a group, analysts predict that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 21st. Investors of record on Thursday, February 20th were given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date was Thursday, February 20th. STERIS's dividend payout ratio (DPR) is presently 48.41%.

Analyst Ratings Changes

Several equities analysts have recently commented on STE shares. Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a research note on Monday, April 7th. Piper Sandler boosted their target price on shares of STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Stephens restated an "overweight" rating and issued a $240.00 price objective on shares of STERIS in a research report on Thursday, February 6th. Finally, JMP Securities restated a "market outperform" rating and issued a $265.00 price objective on shares of STERIS in a report on Thursday, April 10th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $258.75.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.